

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Jenscare Scientific Co., Ltd.
寧波健世科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 9877)

VOLUNTARY ANNOUNCEMENT
LuX-Valve Plus Obtained the EU MDR CE Certification

This announcement is made by Jenscare Scientific Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to provide the shareholders and potential investors of the Company with updated information in relation to the latest business and product development of the Group.

The Board of Directors (the “**Board**”) of the Company is pleased to announce that the Group’s proprietary transvenous tricuspid valve replacement system LuX-Valve Plus has recently obtained CE certification under the EU MDR, achieving a significant milestone of the Company’s internationalization strategy.

LuX-Valve Plus is the world’s second approved transcatheter orthotopic tricuspid valve replacement system. The transvenous access approach further minimizes damage to cardiac tissue. Its radial-force independent septal anchoring design facilitates postoperative right heart remodeling and substantially mitigates the risk of pacemaker implantation. The self-adaptive fabric skirt reduces postoperative paravalvular leakage. The multi-dimensionally steerable delivery system enables precise valve deployment during procedures. Offered in seven sizes ranging from 40 mm to 70 mm, it addresses a wide range of unmet clinical needs for tricuspid regurgitation treatment.

The LuX-Valve product series have been selected for the Expert Panel Scientific Advice Pilot in Europe, granted the FDA Breakthrough Device designation, admitted into the FDA Total Product Life Cycle Advisory Program, and entered the NMPA Special Review Procedure for Innovative Medical Devices. A series of clinical trials of LuX-Valve Plus have been conducted, with some been completed, across major markets including China, Europe and North America. Its clinical data has been prominently presented at numerous world-leading international academic conferences, winning high recognition from global markets and healthcare experts worldwide. Clinical follow-up outcomes demonstrate the device's sustained and outstanding safety and efficacy, with marked reduction in tricuspid regurgitation grade, steady elevation in cardiac function, substantial improvement in quality of life, alongside low adverse event rate.

More than one thousand of patients in need have been implanted with the LuX-Valve product series across dozens of countries and regions spanning five continents, accumulating extensive clinical experience and filling major therapeutic gaps for patients suffering from tricuspid regurgitation, especially those with complex cardiac anatomical structures. The Company is continuously advancing the commercialization of LuX-Valve Plus in Europe and across the globe, with the goal of accomplishing the Company's sustainable internationalization strategy.

Cautionary Statement as required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: There is no assurance that the Company will ultimately market and/or commercialize LuX-Valve Plus successfully. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Jenscare Scientific Co., Ltd.
Mr. PAN Fei
Executive Director and Chief Executive Officer

Hong Kong, 8 July 2026

As at the date of this announcement, the executive Director is Mr. PAN Fei; the non-executive Directors are Mr. LV Shiwen, Mr. TAN Ching, Mr. ZHENG Jiaqi, Ms. XIE Youpei and Mr. CHEN Xinxing; and the independent non-executive Directors are Dr. LIN Shoukang, Ms. DU Jiliu and Dr. MEI Lehe.